Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy

Access Activity

Overview / Abstract:

STATEMENT OF NEED

There are an estimated 13,240 new cases of cervical cancer in the United States each year, and 4,170 people die of the disease. Due to screening and heightened awareness, deaths have declined during the past few decades. However, the malignancy continues to be a global health concern and is considered an epidemic in parts of the world. A significant proportion of patients develop advanced disease, which is rarely curable with available therapies, and treatment is often limited to palliative care. The 5-year overall survival rate is 57% for women with regional disease and 17% for those with distant disease; amongst black women, the prognosis is worse.

TARGET AUDIENCE

Medical oncologists, gynecologic oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with cervical cancer.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Describe the pathophysiology of cervical cancer and the scientific foundation for checkpoint inhibitor therapy
2. Evaluate emerging efficacy and safety data on checkpoint inhibitor therapy in advanced cervical cancer
3. Apply strategies to manage adverse events associated with immune checkpoint inhibitors

Expiration

Sep 27, 2019

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

1.0

Accreditation

ACCME; ANCC

Presenters / Authors / Faculty

Ramez Eskander, MD (Chairperson)
Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences
University of California San Diego

Bradley Monk, MD, FACS, FACOG
Professor, Gynecologic Oncology
University of Arizona and Creighton University

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Merck.

Keywords / Search Terms

i3 Health i3 Health, cervical cancer, gynecological cancer, oncology, gynecology, immunotherapy, immune-related adverse events, CME, CE, webinar, free CE, free CME Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.